查詢結果分析
來源資料
相關文獻
- 肢端肥大症之藥品治療
- Growth Hormone Levels in Patients with Active Acromegaly Treated with Somatostatin Analogues
- Octreotide Effect on Hypersecretion of Growth Hormone in a Patient with Fibrous Dysplasia: A Case Report
- 肢端肥大症的診斷及治療
- 肢端肥大症的內科治療
- The Suppression of Blood Growth Hormone Level by Somatostatin Infusion in Patients with Active Acromegaly
- 肢端肥大症案例報告
- 肢端肥大症的診斷、治療及治療後的長期追蹤
- Somatostatin Analogs的進展與在肢端肥大症的臨床使用經驗談
- 肢端肥大症
頁籤選單縮合
題 名 | Growth Hormone Levels in Patients with Active Acromegaly Treated with Somatostatin Analogues=以體抑素類似物治療肢端肥大症病患後之生長激素變化 |
---|---|
作 者 | 楊博文; 鄭筆聳; 陳涵栩; 林宏達; | 書刊名 | 內科學誌 |
卷 期 | 27:3 2016.06[民105.06] |
頁 次 | 頁149-155 |
分類號 | 415.663 |
關鍵詞 | 肢端肥大症; 生長激素; 體抑素類似物; Acromegaly; Growth hormone; Somatostatin; |
語 文 | 英文(English) |
中文摘要 | 肢端肥大症是因為生長激素分泌過多所引起,並且會引發心血管疾病等併發症,而治療至正常範圍的生長激素濃度後可減少併發症與死亡率。腦下垂體腫瘤切除手術後,常投與體抑素類似物。本文的目的為評估兩種不同的體抑素類似物,即octreotide LAR與lanreotide SR的療效。我們回顧性分析接受octreotide LAR或lanreotide SR治療至少12個月的肢端肥大症病患的臨床資料,評估兩種不同的藥物降低生長激素的效果。本分析包括16位病患,其中9位接受octreotide LAR治療,7位接受lanreotide SR治療。開始接受體抑素類似物治療的平均年齡為51歲,大多數病患為女性與大的腦下垂體腫瘤。接受octreotide LAR平均用藥物治療44個月與lanreotide SR平均用藥物治療54個月治療前後的生長激素濃度分別為6.4 [1.8, 23.7] vs1.24 [0.3, 4.1] (中位數[最小值,最大值],p=0.027)及4.8 [1.4, 109] vs 1.7 [0.3, 23.4] ng/ml(中位數[最小值,最大值],p=0.276)。接受octreotide LAR或lanreotide SR治療之生長激素達到低於2.5 ng/mL的比率分別為66.7% vs 71.4%。體抑素類似物octreotide LAR在肢端肥大症的治療上扮演重要角色,平均治療44個月後,生長激素的濃度有顯著的下降。 |
英文摘要 | Acromegaly is characterized by excessive growth hormone (GH) secretion and may result in high morbidity and mortality, particularly from cardiovascular disease. Normalized serum GH levels may abolish this untoward effect. Somatostatin analogues (SA) are usually prescribed following unsuccessful transsphenoid surgery for pituitary adenomas. The purpose of this analysis is to evaluate the effects of two SA, octreotide LAR and lanreotide SR, on GH levels in patients with active acromegaly. We reviewed the clinical data of patients with active acromegaly who were treated with SA for at least 12 months. The efficacy of octreotide LAR and lanreotide SR in lowering GH levels was retrospectively investigated. Sixteen patients with active acromegaly were enrolled in the analysis. Nine patients received octreotide LAR and 7 received lanreotide SR. The mean age when initiating SA therapy was 51 years, and the majority of patients were women and had macroadenomas. GH concentrations before and after SA treatment were 6.4 [1.8, 23.7] vs. 1.24 [0.3, 4.1] ng/ ml (median [minimum, maximum], p=0.027) for the octreotide LAR group and 4.8 [1.4, 109] vs. 1.7 [0.3, 23.4] ng/ml (median [minimum, maximum], p=0.276) for the lanreotide SR group after a mean 44 months and 54 months of treatment, respectively. The rates of serum GH concentration below 2.5 ng/mL for octreotide LAR group and lanreotide SR group were 66.7% and 71.4%, respectively. In conclusion, octreotide LAR play a significant role in adjunctive therapy for active acromegaly, while GH levels declined significantly after a mean 44 months treatment. |
本系統中英文摘要資訊取自各篇刊載內容。